{"id":179229,"date":"2018-04-13T18:00:00","date_gmt":"2018-04-13T23:00:00","guid":{"rendered":"https:\/\/www.panix.com\/~msaroff\/40years\/2018\/04\/13\/i-propose-renaming-goldman-sachs-to-sirius-cybernetics-corporation\/"},"modified":"2018-04-13T18:00:00","modified_gmt":"2018-04-13T23:00:00","slug":"i-propose-renaming-goldman-sachs-to-sirius-cybernetics-corporation","status":"publish","type":"post","link":"https:\/\/www.panix.com\/~msaroff\/40years\/2018\/04\/13\/i-propose-renaming-goldman-sachs-to-sirius-cybernetics-corporation\/","title":{"rendered":"I Propose Renaming Goldman Sachs to &#8220;Sirius Cybernetics Corporation&#8221;"},"content":{"rendered":"<p>Because the latest bit of analysis on healthcare from these guys,  basically says that, <a href=\"https:\/\/arstechnica.com\/tech-policy\/2018\/04\/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say\/\">there is no money on curing disease, we need to work to make everything chronic<\/a>.<\/p>\n<p>I believe the phrase, &#8220;A bunch of mindless jerks who&#8217;ll be the first against the wall when the revolution comes,&#8221; should apply here:<\/p>\n<blockquote><p><span style=\"color: blue;\">One-shot cures for diseases are not great for business\u2014more specifically, they\u2019re bad for longterm profits\u2014Goldman Sachs analysts noted in an April 10 report for biotech clients, <a href=\"https:\/\/www.cnbc.com\/2018\/04\/11\/goldman-asks-is-curing-patients-a-sustainable-business-model.html\">first reported by CNBC<\/a>. <\/p>\n<p>The investment banks\u2019 report, titled \u201cThe Genome Revolution,\u201d asks clients the touchy question: \u201cIs curing patients a sustainable business model?\u201d The answer may be \u201cno,\u201d according to follow-up information provided. <\/p>\n<p>Analyst Salveen Richter and colleagues laid it out: <\/span><\/p>\n<blockquote><p><span style=\"color: blue;\">The potential to deliver \u201cone shot cures\u201d is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies&#8230; While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. <\/span><\/p><\/blockquote>\n<p><span style=\"color: blue;\"><br \/>For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company\u2019s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.<\/span><\/p><\/blockquote>\n<p>I want the guillotine concession on these rat-f%$#s. <\/p>\n<p>I&#8217;d be a wealthy man.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Because the latest bit of analysis on healthcare from these guys, basically says that, there is no money on curing disease, we need to work to make everything chronic. I believe the phrase, &#8220;A bunch of mindless jerks who&#8217;ll be the first against the wall when the revolution comes,&#8221; should apply here: One-shot cures for &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[365,364,456,463,567],"class_list":["post-179229","post","type-post","status-publish","format-standard","hentry","tag-business","tag-evil","tag-finance","tag-healthcare","tag-pharma"],"_links":{"self":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/179229"}],"collection":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/comments?post=179229"}],"version-history":[{"count":0,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/179229\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/media?parent=179229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/categories?post=179229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/tags?post=179229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}